News Amgen's Horizon buyout delivers Sjögren's disease win Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
News UK backs startup Potential Sciences' AI-powered drug hunt UK startup Potential Sciences emerged from stealth today with a sizeable seed funding round and an ambition to transform drug discovery with AI.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.